The company, co-founded by CEO Adam Hanina and Chief Scientific Officer Martin Schrimpf, is building digital brain models that simulate how neural tissue responds to sensory or direct stimulation. These "in silico" models are designed to bypass the traditional, slow pace of in vivo testing, offering a faster route to discovering treatments for cognitive dysfunction. By treating the brain’s activity as a form of code, the team intends to use neural interfaces to rewrite or influence patterns of activity directly.

To support this mission, the team has added significant academic and industry expertise. Scientific fellows Jim DiCarlo of MIT and Dan Yamins of Stanford join advisor Stephen Wolfram, the creator of Mathematica. On the technical side, Katherine Fairchild, formerly of Digital Diagnostics, joins as CTO, while Ben Lönnqvist takes the role of Head of NeuroAI. This collective expertise focuses on two distinct objectives: utilizing AI to treat the human brain, and extracting principles from biological intelligence to build safer, more human-centered machine learning models. The company currently holds over 30 patents and has secured backing from the National Institutes of Health and the Swiss government.